← Back to all signals
RESEARCH PAPER ANALYSIS

Characteristics and outcomes of primary and secondary resistance to immune checkpoint inhibitors in hepatocellular carcinoma.

AI interpretation is pending for this paper.

Open original publication →
PMID40481877
JournalCancer immunology, immunotherapy : CII
Publication Date2025-06-07
Ingested2026-08-02 12:04 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

Resistance limits the efficacy and durability of immune checkpoint inhibitors (ICIs) in hepatocellular carcinoma (HCC). Therefore, we conducted a retrospective cohort study to investigate the outcomes and characteristics of HCC patients with resistance to immunotherapy. Patients with HCC who have received ICIs at Eastern Hepatobiliary Surgery Hospital between 2016 and 2021 were retrospectively screened and divided into primary resistance, secondary resistance, and durable response group. Time to progression (TTP), overall survival (OS), subsequent management and post-progression survival (PPS) were analyzed. Of 496 patients included, 229 (46.2%) and 141 (28.4%) patients developed primary and secondary resistance, and 126 (25.4%) patients achieved a durable response, the median TTP was 2.83 [2.56-3.09] months, 11.93 [10.45-13.40] months, and not reached, respectively, whereas the median OS was 12.83 [10.36-15.30] months, 31.53 [28.09-34.97] and not reached, respectively. Multivariate logistic regression revealed that Child-Pugh score, BCLC stage, and combined systemic therapies (ICI plus bevacizumab or lenvatinib versus ICI monotherapy) were independently associated with primary resistance, and only combined systemic therapies (ICI plus bevacizumab versus ICI monotherapy) were independently associated with secondary resistance. AFP levels were independently associated with PPS in patients with primary resistance, while post-progression therapies (ICI-based therapies versus others) were independently associated with PPS in patients with resistance. The risk of resistance was notably lower in patients receiving the combination of ICI plus bevacizumab. High AFP levels were associated with the survival of patients with primary resistance. ICI-based maintenance therapy after resistance may provide a significant survival advantage for HCC patients.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 [Evaluation of the Educational Effects of Cervical Cancer and HPV Vaccine Education for Junior High School Students]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 41.7 2 The National Couples' Health and Time Stress Biology Study (NCHAT-BIO): Wave 1 Methodology Report and Wave 3 Preview. Biopsychosocial science and medicine 65.7 3 Communication quality shapes the sustainability of pediatric early warning system. BMC health services research 63.4 4 Treatment of children with Kawasaki disease complicated by selective IgA deficiency using immunoglobulin preparations: a case report. BMC pediatrics 56.24 5 Hotspot mutations and tumour spectrum in von Hippel-Lindau syndrome: genotype-phenotype analysis of a large Chinese cohort. Journal of cancer research and clinical oncology 64.7 6 Perioperative outcomes and appendiceal malignancy in elderly patients with acute appendicitis: a comparative retrospective cohort study. Langenbeck's archives of surgery 68.0 7 Posttransplant lymphoproliferative disorders following hematopoietic stem cell transplantation: a clinicopathological study of a large single-center cohort. Annals of hematology 66.7 8 Therapeutic NAMPT inhibition reveals a targetable metabolic vulnerability in neuroblastoma. Journal of experimental & clinical cancer research : CR 60.04 9 Comparison of thyroglossal duct cysts in adults and children: 11 years of clinical experience. Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale 67.8 10 Adult Pott's Puffy Tumor in the ED. Cureus 49.9 11 Long-term remission after surgical excision and minimal rituximab exposure in localized high-grade B-cell lymphoma with 11q aberration. Journal of clinical and experimental hematopathology : JCEH 62.56 12 Sixteen-year changes in hazardous metal(loid)s in urban topsoils: Land-use-specific enrichment and PM₁₀-based human health risk. Journal of hazardous materials 58.7 13 Mesenchymal Malignant Transformation in Metanephric Stromal Tumor: Expanding the Pathologic Spectrum of Metanephric Neoplasia. Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society 55.0 14 Intramuscular Myxoma of the Shoulder in Neurofibromatosis Type 1. Cancer diagnosis & prognosis 49.9 15 Hepatic Tumoral Calcinosis in a Patient With Obesity and Metabolic Syndrome: A Case Report. Case reports in surgery 47.5 16 A Large Multicenter Cohort of Ataxia-Telangiectasia: Clinical, Immunologic, Genetic, and Survival Outcomes. European journal of neurology 68.62 17 Effects of insulin resistance on pregnancy outcomes and complications in women with polycystic ovary syndrome. The Journal of international medical research 67.0 18 Genetic testing considerations for hereditary duodenopancreatic neuroendocrine tumors. Journal of neuroendocrinology 62.5 19 Clinical Features, Treatments, and Outcomes of an International Cohort of 96 Children with Takayasu Arteritis. ACR open rheumatology 67.74 20 It's a Trap! CDK8 Inhibition Reveals a Shared Vulnerability through Mediator Trapping in Fusion-Driven Pediatric Sarcomas. Cancer discovery 56.5 21 Recruitment, Retention, and Patient Engagement of Adolescents and Young Adult Cancer Survivors in Psycho-Oncology Research: A Qualitative Study. Journal of adolescent and young adult oncology 56.0 22 The Role of Genetic Profiling in Pediatric Brain Tumors. Balkan medical journal 47.5 23 Voices in Molecular Pharmaceutics: Meet Dr. Ritika Gupta Who Seeks to Light up Pediatric Tumors with Targeted Fluorescence Imaging Agents. Molecular pharmaceutics 47.5 24 Patterns of Pediatric Cancer Care at a Tertiary Center in Pakistan: A Hospital-Based Registry Analysis. Pediatric blood & cancer 66.9 25 Natural Killer Cell-Based Immunotherapy in Retinoblastoma: Biological Basis, Preclinical Evidence, and Translational Challenges. Pediatric blood & cancer 66.5 26 Perioperative Management of Children, Adolescents and Young Adults Undergoing Surgical Treatment for Oncologic Thoracic Disease: Retrospective Single-Center Analysis. Pediatric blood & cancer 67.14 27 A Clot Before the Cancer: Cerebral Venous Sinus Thrombosis as the Initial Presentation of Childhood Acute Leukemia-A Case Report and Literature Review. Pediatric blood & cancer 39.0 28 Creation of a Tailored Social Media Campaign to Educate Adolescents and Young Adults About Clinical Trials: The Talk to Me Study. Journal of adolescent and young adult oncology 72.2 29 Re: Robot-assisted minimally invasive surgery in paediatric neuroblastoma: does the actual technology truly expand selection criteria? Pediatric surgery international 47.5 30 Enablers and barriers to human papillomavirus vaccination implementation among key stakeholders in Ethiopia: A qualitative study. PloS one 62.5 31 Cohort Profile: The Adolescent and Young Adult Tracking Engagement and Management Skills (AYA TEAMS) longitudinal cohort of childhood cancer survivors in the United States. PloS one 67.4 32 Identifying novel genomic alterations in relapsed childhood B-ALL: a report from the Children's Oncology Group. Blood 84.42
PATIENT-FRIENDLY SUMMARY

Characteristics and outcomes of primary and secondary resistance to immune checkpoint inhibitors in hepatocellular carcinoma.

For education only—not personal medical advice.

Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic